INTERCEPT PHARMACEUTICALS IN (ICPT) Fundamental Analysis & Valuation

NASDAQ:ICPT • US45845P1084

Current stock price

19 USD
+0.04 (+0.21%)
At close:
19 USD
0 (0%)
After Hours:

This ICPT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. ICPT Profitability Analysis

1.1 Basic Checks

  • ICPT had negative earnings in the past year.
  • In the past year ICPT has reported a negative cash flow from operations.
ICPT Yearly Net Income VS EBIT VS OCF VS FCFICPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 0 200M -200M -400M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -15.67%, ICPT belongs to the top of the industry, outperforming 84.91% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -85.76%, ICPT is in line with its industry, outperforming 45.94% of the companies in the same industry.
Industry RankSector Rank
ROA -15.67%
ROE -85.76%
ROIC N/A
ROA(3y)-8.21%
ROA(5y)-26.21%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ICPT Yearly ROA, ROE, ROICICPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 -500 -1K -1.5K -2K

1.3 Margins

  • ICPT has a better Gross Margin (99.80%) than 99.17% of its industry peers.
  • In the last couple of years the Gross Margin of ICPT has remained more or less at the same level.
  • The Profit Margin and Operating Margin are not available for ICPT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 99.8%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.45%
GM growth 5Y0.15%
ICPT Yearly Profit, Operating, Gross MarginsICPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. ICPT Health Analysis

2.1 Basic Checks

  • ICPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ICPT has more shares outstanding than it did 1 year ago.
  • The debt/assets ratio for ICPT has been reduced compared to a year ago.
ICPT Yearly Shares OutstandingICPT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M
ICPT Yearly Total Debt VS Total AssetsICPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M

2.2 Solvency

  • Based on the Altman-Z score of -5.03, we must say that ICPT is in the distress zone and has some risk of bankruptcy.
  • ICPT has a Altman-Z score of -5.03. This is in the lower half of the industry: ICPT underperforms 66.17% of its industry peers.
  • ICPT has a Debt/Equity ratio of 3.12. This is a high value indicating a heavy dependency on external financing.
  • Looking at the Debt to Equity ratio, with a value of 3.12, ICPT is doing worse than 85.41% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 3.12
Debt/FCF N/A
Altman-Z -5.03
ROIC/WACCN/A
WACC10.19%
ICPT Yearly LT Debt VS Equity VS FCFICPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 200M -200M 400M

2.3 Liquidity

  • ICPT has a Current Ratio of 4.22. This indicates that ICPT is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 4.22, ICPT perfoms like the industry average, outperforming 42.45% of the companies in the same industry.
  • A Quick Ratio of 4.22 indicates that ICPT has no problem at all paying its short term obligations.
  • The Quick ratio of ICPT (4.22) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.22
Quick Ratio 4.22
ICPT Yearly Current Assets VS Current LiabilitesICPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. ICPT Growth Analysis

3.1 Past

  • ICPT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -125.05%.
  • Looking at the last year, ICPT shows a quite strong growth in Revenue. The Revenue has grown by 14.64% in the last year.
  • Measured over the past years, ICPT shows a quite strong growth in Revenue. The Revenue has been growing by 16.88% on average per year.
EPS 1Y (TTM)-125.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-98.97%
Revenue 1Y (TTM)14.64%
Revenue growth 3Y4.27%
Revenue growth 5Y16.88%
Sales Q2Q%14.44%

3.2 Future

  • The Earnings Per Share is expected to decrease by -22.89% on average over the next years. This is quite bad
  • The Revenue is expected to grow by 1.71% on average over the next years.
EPS Next Y-122.07%
EPS Next 2Y-41.22%
EPS Next 3Y-33.62%
EPS Next 5Y-22.89%
Revenue Next Year3.67%
Revenue Next 2Y6.35%
Revenue Next 3Y4.21%
Revenue Next 5Y1.71%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ICPT Yearly Revenue VS EstimatesICPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
ICPT Yearly EPS VS EstimatesICPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 5 -5 -10 -15

More info and screens

Find the best growth stocksShow best growing peers

2

4. ICPT Valuation Analysis

4.1 Price/Earnings Ratio

  • ICPT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Based on the Price/Forward Earnings ratio of 9.11, the valuation of ICPT can be described as reasonable.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of ICPT indicates a rather cheap valuation: ICPT is cheaper than 99.00% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 37.39. ICPT is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 9.11
ICPT Price Earnings VS Forward Price EarningsICPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ICPT Per share dataICPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

  • ICPT's earnings are expected to decrease with -33.62% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.22%
EPS Next 3Y-33.62%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ICPT Dividend Analysis

5.1 Amount

  • No dividends for ICPT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

ICPT Fundamentals: All Metrics, Ratios and Statistics

INTERCEPT PHARMACEUTICALS IN

NASDAQ:ICPT (11/7/2023, 8:02:20 PM)

After market: 19 0 (0%)

19

+0.04 (+0.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)02-29
Inst Owners0.17%
Inst Owner Change0%
Ins Owners10.38%
Ins Owner Change0%
Market Cap794.39M
Revenue(TTM)317.68M
Net Income(TTM)-61.61M
Analysts70
Price Target19.38 (2%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)95.4%
Min EPS beat(2)73.02%
Max EPS beat(2)117.78%
EPS beat(4)2
Avg EPS beat(4)-7.36%
Min EPS beat(4)-203.66%
Max EPS beat(4)117.78%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.75%
Min Revenue beat(2)-1.65%
Max Revenue beat(2)3.15%
Revenue beat(4)1
Avg Revenue beat(4)-2.32%
Min Revenue beat(4)-7.75%
Max Revenue beat(4)3.15%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.63%
PT rev (3m)24.59%
EPS NQ rev (1m)0%
EPS NQ rev (3m)660.22%
EPS NY rev (1m)0%
EPS NY rev (3m)3.74%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.01%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.24%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 9.11
P/S 2.5
P/FCF N/A
P/OCF N/A
P/B 11.06
P/tB 11.06
EV/EBITDA N/A
EPS(TTM)-1.33
EYN/A
EPS(NY)2.09
Fwd EY10.98%
FCF(TTM)-1.5
FCFYN/A
OCF(TTM)-1.51
OCFYN/A
SpS7.6
BVpS1.72
TBVpS1.72
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -15.67%
ROE -85.76%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 99.8%
FCFM N/A
ROA(3y)-8.21%
ROA(5y)-26.21%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.45%
GM growth 5Y0.15%
F-Score3
Asset Turnover0.81
Health
Industry RankSector Rank
Debt/Equity 3.12
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 49.34%
Cap/Sales 0.06%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.22
Quick Ratio 4.22
Altman-Z -5.03
F-Score3
WACC10.19%
ROIC/WACCN/A
Cap/Depr(3y)78.24%
Cap/Depr(5y)53.92%
Cap/Sales(3y)0.53%
Cap/Sales(5y)0.43%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-125.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-98.97%
EPS Next Y-122.07%
EPS Next 2Y-41.22%
EPS Next 3Y-33.62%
EPS Next 5Y-22.89%
Revenue 1Y (TTM)14.64%
Revenue growth 3Y4.27%
Revenue growth 5Y16.88%
Sales Q2Q%14.44%
Revenue Next Year3.67%
Revenue Next 2Y6.35%
Revenue Next 3Y4.21%
Revenue Next 5Y1.71%
EBIT growth 1Y30.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-9.22%
EBIT Next 3Y46.24%
EBIT Next 5YN/A
FCF growth 1Y2.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.28%
OCF growth 3YN/A
OCF growth 5YN/A

INTERCEPT PHARMACEUTICALS IN / ICPT Fundamental Analysis FAQ

What is the ChartMill fundamental rating of INTERCEPT PHARMACEUTICALS IN (ICPT) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ICPT.


What is the valuation status of INTERCEPT PHARMACEUTICALS IN (ICPT) stock?

ChartMill assigns a valuation rating of 2 / 10 to INTERCEPT PHARMACEUTICALS IN (ICPT). This can be considered as Overvalued.


Can you provide the profitability details for INTERCEPT PHARMACEUTICALS IN?

INTERCEPT PHARMACEUTICALS IN (ICPT) has a profitability rating of 2 / 10.


What is the expected EPS growth for INTERCEPT PHARMACEUTICALS IN (ICPT) stock?

The Earnings per Share (EPS) of INTERCEPT PHARMACEUTICALS IN (ICPT) is expected to decline by -122.07% in the next year.